Inhibitory peptides of viral infection

Patent metadata

Field	Value
Publication number	US-10308685-B2
Application number	US-201715605877-A
Country	US
Kind code	B2
Filing date	May 25, 2017
Priority date	Jul 17, 2014
Publication date	Jun 4, 2019
Grant date	Jun 4, 2019

Abstract

Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.

First claim

The invention claimed is:

1. A heparin binding peptide consisting of an amino acid sequence at least 95% identical to the amino acid sequence set forth as any one of SEQ ID NOs: 3-10.

2. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected with a virus reduces viral infection in the subject.

3. The heparin binding peptide of claim 2 , wherein administration of the heparin binding peptide to the subject infected with the virus reduces viral infection in the subject by at least 60%.

4. The heparin binding peptide of claim 2 , wherein the virus is an enveloped DNA virus or enveloped RNA virus.

5. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected with herpesvirus reduces herpesvirus infection in the subject.

6. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected with cytomegalovirus reduces cytomegalovirus infection in the subject.

7. The heparin binding peptide of claim 1 , wherein administration of the heparin binding peptide to a subject infected human immunodeficiency virus (HIV) infection reduces HIVs infection in the subject.

8. The heparin binding peptide of claim 1 , wherein the heparin-binding peptide is a D-form peptide.

9. A heparin binding peptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth as any one of SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 10.

10. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected with a virus reduces viral infection in the subject.

11. The heparin binding peptide of claim 10 , wherein administration of the heparin binding peptide to the subject infected with the virus reduces viral infection in the subject by at least 60%.

12. The heparin binding peptide of claim 10 , wherein the virus is an enveloped DNA virus or enveloped RNA virus.

13. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected with herpesvirus reduces herpesvirus infection in the subject.

14. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected with cytomegalovirus reduces cytomegalovirus infection in the subject.

15. The heparin binding peptide of claim 9 , wherein administration of the heparin binding peptide to a subject infected human immunodeficiency virus (HIV) infection reduces HIVs infection in the subject.

16. The heparin binding peptide of claim 9 , wherein the heparin-binding peptide is a D-form peptide.

Assignees

• Univ Tennessee Res Found

Inventors

• Wall Jonathan S
• Sparer Timothy E
• Kennel Stephen J

Classifications

• C07K14/045

  Cytomegalovirus · CPC title

• C07K14/001

  by chemical synthesis · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• C07K14/035

  Herpes simplex virus I or II · CPC title

• A61K38/16 Primary

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title